Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Global Health

Sterling to develop low-cost COVID-19 therapy

by Rick Mullin
December 4, 2021 | A version of this story appeared in Volume 99, Issue 44

 

The drug services firm Sterling Pharma Solutions and the Manchester Institute of Biotechnology (MIB) plan to scale up a low-cost route to molnupiravir, a Merck & Co. antiviral recently approved in the UK to treat COVID-19. The route, developed by MIB with funding from the Bill and Melinda Gates Foundation, uses a novel enzyme, cytidine aminotransferase, which is expected to lower production costs. At its site in Dudley, England, Sterling plans to produce multikilogram quantities of molnupiravir for generic drug firms that will make pills for low-income countries.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.